OptimizeRx Corp. Hits New 52-Week High of $21.99, Up 90% Yearly

OptimizeRx Corp. has reached a significant milestone by hitting a new 52-week high of USD 21.99 on October 24, 2025. This achievement marks a remarkable increase in the stock's performance, reflecting a 90.18% rise over the past year, significantly outperforming the S&P 500, which has seen a gain of 16.9% during the same period.
As a microcap company in the software products industry, OptimizeRx Corp. has a market capitalization of USD 340 million. Despite its recent stock performance, the company remains in a loss-making position, with a return on equity of -1.99%. The stock's price-to-book ratio stands at 2.85, indicating how the market values the company's equity relative to its book value.

With a debt-to-equity ratio of 0.10, OptimizeRx Corp. maintains a relatively low level of debt, which may provide some financial stability. However, the company does not offer a dividend yield, reflecting its focus on growth rather than returning capital to shareholders. The stock's previous 52-week low was recorded at USD 3.78, highlighting the significant upward movement in its price.